EMILY NEWLIN: Open Payments
NPI 1265086565 · LAFAYETTE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,109 in 92 payments from 18 companies in 2025. Trend: 2023 $105 · 2024 $1,726 · 2025 $2,109
Food & beverage: $2,099Education: $9
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 20 | $781 |
| GENZYME CORPORATION | 15 | $226 |
| ABBVIE INC. | 14 | $225 |
| Madrigal Pharmaceuticals | 9 | $206 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $150 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $85 |
| Regeneron Healthcare Solutions, Inc. | 4 | $71 |
| PFIZER INC. | 3 | $64 |
| Ferring Pharmaceuticals Inc. | 3 | $53 |
| NeurAxis, Inc. | 1 | $49 |
Products named: TREMFYA, DUPIXENT, REZDIFFRA, RINVOQ, ENTYVIO, XIFAXAN, SKYRIZI, EOHILIA.
Industry payments across IN — which companies pay providers there.
